Atheer Zgair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Atheer Zgair has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Pavel Gershkovich
School of Pharmacy
15 shared publications - Jong Bong Lee
School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK
11 shared publications - David A. Barrett
Centre for Analytical Bioscience, Advanced Materials and Healthcare Division, School of Pharmacy, University of Nottingham, Nottingham, UK
6 shared publications Peter M. Fischer
School of Pharmacy & Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
5 shared publications- Peter M. Fischer
School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK
5 shared publications Tae Hwan Kim
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
5 shared publications
Latest Publications
- Open Access
Antidepressant-like Effects of Orthosiphon stamineus: Integrated Evidence from In Silico, In Vitro, and a Reserpine-Induced Depression Model
Background: Traditional antidepressants are associated with undesirable side effects, limited efficacy, and delayed therapeutic responses. Natural products have emerged as a potential alternative to these drugs. This research aimed to investigate the antidepressant-like activity and possible mechanism of Orthosiphon stamineus (OS) leaf ethanolic extract. Methods: Molecular docking and in vitro studies were performed to assess the inhibitory activity of ethanolic extracts of OS leaves against the monoamine oxidase (MAO-A) enzyme. Behavioral tests were used to evaluate the antidepressant-like activity of the 95% ethanol extract in reserpine-treated rats, followed by histopathological examination and measurement of hippocampal serotonin (5-HT), norepinephrine (NE), and brain-derived neurotrophic factor (BDNF). Results: The main active compounds, particularly rosmarinic acid and eupatorin, exhibited favorable binding affinities to the MAO-A active site. The 95% and 50% ethanol extracts of OS showed dose-dependent MAO-A inhibitory activity with ICs50 of 88.67 and 103.2 µg/mL, respectively. The 95% ethanol extract of OS leaves showed a significant reduction in immobility time, restored locomotor activity, and preserved hippocampal morphology. Notably, the higher dose of OS extract (150 mg/kg) significantly enhanced hippocampal expression of 5-HT and NE, with a moderate upregulation of BDNF. Conclusions: These findings suggest that the 95% ethanol extract of OS leaves exhibits promising antidepressant-like effects, which may be mediated through monoamine modulation and BDNF expression and partially through MAO-A enzyme inhibition.
Open AccessAntidepressant-like Effects of Orthosiphon stamineus: Integrated Evidence from In Silico, In Vitro, and a Reserpine-Induced Depression Model
Background: Traditional antidepressants are associated with undesirable side effects, limited efficacy, and delayed therapeutic responses. Natural products have emerged as a potential alternative to these drugs. This research aimed to investigate the antidepressant-like activity and possible mechanism of Orthosiphon stamineus (OS) leaf ethanolic extract. Methods: Molecular docking and in vitro studies were performed to assess the inhibitory activity of ethanolic extracts of OS leaves against the monoamine oxidase (MAO-A) enzyme. Behavioral tests were used to evaluate the antidepressant-like activity of the 95% ethanol extract in reserpine-treated rats, followed by histopathological examination and measurement of hippocampal serotonin (5-HT), norepinephrine (NE), and brain-derived neurotrophic factor (BDNF). Results: The main active compounds, particularly rosmarinic acid and eupatorin, exhibited favorable binding affinities to the MAO-A active site. The 95% and 50% ethanol extracts of OS showed dose-dependent MAO-A inhibitory activity with ICs50 of 88.67 and 103.2 µg/mL, respectively. The 95% ethanol extract of OS leaves showed a significant reduction in immobility time, restored locomotor activity, and preserved hippocampal morphology. Notably, the higher dose of OS extract (150 mg/kg) significantly enhanced hippocampal expression of 5-HT and NE, with a moderate upregulation of BDNF. Conclusions: These findings suggest that the 95% ethanol extract of OS leaves exhibits promising antidepressant-like effects, which may be mediated through monoamine modulation and BDNF expression and partially through MAO-A enzyme inhibition.
- Open Access
Aldose Reductase Inhibition by Orthosiphon stamineus Extracts and Constituents Suggests Antioxidant Potential
Background/Objectives: Aldose reductase (AR) plays a crucial role in the accumulation of oxidative factors that lead to oxidative stress-related neuroinflammation. This study aims to find a novel agent from natural sources that can inhibit AR. Methods: Different extracts of Orthosiphon stamineus Benth (OS) leaves and its active constituents, eupatorin (EUP), rosmarinic acid (RA), sinensetin (SEN) and 3-hydroxy-5,6,7,4-tetramethoxyflavone (TMF), were used to identify the potential inhibition effect of AR. A new high-performance liquid chromatography (HPLC) method was developed to determine these phytochemicals using the Shimadzu LC-20AD HPLC system. In addition, the in vitro inhibition effect of OS ethanol extracts (95% and 50%) and OS components EUP, RA, and SEN was investigated in recombinant AR (AKR1B1). Results: In this study, the developed HPLC method was precise and accurate, and demonstrated clear separation of the four compounds—EUP, RA, SEN, and TMF—in the ethanolic extract. The contents of the four selected compounds—EUP, RA, SEN, and TMF—in 95% ethanolic extract were 2.35, 11.91, 0.94, and 0.18%, respectively. RA showed the highest concentration among the selected compounds, indicating that RA is the major constituent of this plant. The in vitro assay showed significant inhibition of the AR enzyme by RA and OS ethanol extracts 95% and 50% (IC50: 41.42 µM; 63.42 µg/mL and 93.22 µg/mL, respectively). Conclusions: The ethanolic extract of OS and RA could be a promising therapeutics option for the treatment of oxidative stress-related neuroinflammation disorders by inhibiting AR.
Open AccessAldose Reductase Inhibition by Orthosiphon stamineus Extracts and Constituents Suggests Antioxidant Potential
Background/Objectives: Aldose reductase (AR) plays a crucial role in the accumulation of oxidative factors that lead to oxidative stress-related neuroinflammation. This study aims to find a novel agent from natural sources that can inhibit AR. Methods: Different extracts of Orthosiphon stamineus Benth (OS) leaves and its active constituents, eupatorin (EUP), rosmarinic acid (RA), sinensetin (SEN) and 3-hydroxy-5,6,7,4-tetramethoxyflavone (TMF), were used to identify the potential inhibition effect of AR. A new high-performance liquid chromatography (HPLC) method was developed to determine these phytochemicals using the Shimadzu LC-20AD HPLC system. In addition, the in vitro inhibition effect of OS ethanol extracts (95% and 50%) and OS components EUP, RA, and SEN was investigated in recombinant AR (AKR1B1). Results: In this study, the developed HPLC method was precise and accurate, and demonstrated clear separation of the four compounds—EUP, RA, SEN, and TMF—in the ethanolic extract. The contents of the four selected compounds—EUP, RA, SEN, and TMF—in 95% ethanolic extract were 2.35, 11.91, 0.94, and 0.18%, respectively. RA showed the highest concentration among the selected compounds, indicating that RA is the major constituent of this plant. The in vitro assay showed significant inhibition of the AR enzyme by RA and OS ethanol extracts 95% and 50% (IC50: 41.42 µM; 63.42 µg/mL and 93.22 µg/mL, respectively). Conclusions: The ethanolic extract of OS and RA could be a promising therapeutics option for the treatment of oxidative stress-related neuroinflammation disorders by inhibiting AR.
- Open Access
- 1 April 2025
- Published by University of Anbar in Al- Anbar Medical Journal
- Vol. 21 (2) , 135-139
Taurine Could Affect the Progression of Age-related Cataract: A Single-arm Pre-post Intervention Study
Background: Oxidative stress is the principal contributor to the pathogenesis and progression of age-related cataract (ARC), the most prevalent type of cataract.Objectives: The current study was designed to evaluate the therapeutic potential of taurine to prevent the progression of the nuclear subtype of ARC.Material and Methods: In total, 61 participants, 115 eyes with the grade I or II nuclear subtype of ARC, were included in this single-arm, open-label, pre-post intervention clinical trial. Participants were instructed to apply taurine-containing eye drops four times a day for one year. Ophthalmological examinations, including best corrected visual acuity (BCVA), were performed at the baseline visit and subsequent follow-up visits at 3-month intervals for one year. The trial was registered at https://clinicaltrials.gov/study/NCT06639711.Results: The study cohort comprised 15 males (24.6%) and 46 females (75.4%). The median age of the participants was 62 years (IQRs 58-68). At the baseline visit, the mean logMAR BCVA was 0.2 ± 0.19. In this study, BCVA was stable throughout the study (Wald Chi-square = 1.254, P-value = 0.534). Additionally, age and female sex were found to have significant deteriorating effects on BCVA (P-value < 0.001 and P-value = 0.028, respectively).Conclusion: This interventional study demonstrated that taurine-containing eye drops can serve as an effective therapeutic option to prevent further deterioration of BCVA and potentially inhibit the progression of nuclear ARC. In addition, age and sex were key factors that influenced the progression of ARC. Further studies incorporating randomized controlled designs, extended follow-up, and multiple centers are recommended.
- 1 April 2025
- Published by University of Anbar in Al- Anbar Medical Journal
- Vol. 21 (2) , 135-139
Open AccessTaurine Could Affect the Progression of Age-related Cataract: A Single-arm Pre-post Intervention Study
Background: Oxidative stress is the principal contributor to the pathogenesis and progression of age-related cataract (ARC), the most prevalent type of cataract.Objectives: The current study was designed to evaluate the therapeutic potential of taurine to prevent the progression of the nuclear subtype of ARC.Material and Methods: In total, 61 participants, 115 eyes with the grade I or II nuclear subtype of ARC, were included in this single-arm, open-label, pre-post intervention clinical trial. Participants were instructed to apply taurine-containing eye drops four times a day for one year. Ophthalmological examinations, including best corrected visual acuity (BCVA), were performed at the baseline visit and subsequent follow-up visits at 3-month intervals for one year. The trial was registered at https://clinicaltrials.gov/study/NCT06639711.Results: The study cohort comprised 15 males (24.6%) and 46 females (75.4%). The median age of the participants was 62 years (IQRs 58-68). At the baseline visit, the mean logMAR BCVA was 0.2 ± 0.19. In this study, BCVA was stable throughout the study (Wald Chi-square = 1.254, P-value = 0.534). Additionally, age and female sex were found to have significant deteriorating effects on BCVA (P-value < 0.001 and P-value = 0.028, respectively).Conclusion: This interventional study demonstrated that taurine-containing eye drops can serve as an effective therapeutic option to prevent further deterioration of BCVA and potentially inhibit the progression of nuclear ARC. In addition, age and sex were key factors that influenced the progression of ARC. Further studies incorporating randomized controlled designs, extended follow-up, and multiple centers are recommended.
- 1 September 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (5) , 103033
Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study
- 1 September 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (5) , 103033
Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study
- Open Access
- 27 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1349
Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle
Oral sesame oil-based formulation facilitates the delivery of poorly water-soluble drug cannabidiol (CBD) to the lymphatic system and blood circulation. However, this natural oil-based formulation also leads to considerable variability in absorption of CBD. In this work, the performance of lipid-based formulations with the addition of medium-chain triglyceride (MCT) or surfactants to the sesame oil vehicle has been tested in vitro and in vivo using CBD as a model drug. The in vitro lipolysis has shown that addition of the MCT leads to a higher distribution of CBD into the micellar phase. Further addition of surfactants to MCT-containing formulations did not improve distribution of the drug into the micellar phase. In vivo, formulations containing MCT led to lower or similar concentrations of CBD in serum, lymph and MLNs, but with reduced variability. MCT improves the emulsification and micellar solubilization of CBD, but surfactants did not facilitate further the rate and extent of lipolysis. Even though addition of MCT reduces the variability, the in vivo performance for the extent of both lymphatic transport and systemic bioavailability remains superior with a pure natural oil vehicle.
- 27 August 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1349
Open AccessInclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle
Oral sesame oil-based formulation facilitates the delivery of poorly water-soluble drug cannabidiol (CBD) to the lymphatic system and blood circulation. However, this natural oil-based formulation also leads to considerable variability in absorption of CBD. In this work, the performance of lipid-based formulations with the addition of medium-chain triglyceride (MCT) or surfactants to the sesame oil vehicle has been tested in vitro and in vivo using CBD as a model drug. The in vitro lipolysis has shown that addition of the MCT leads to a higher distribution of CBD into the micellar phase. Further addition of surfactants to MCT-containing formulations did not improve distribution of the drug into the micellar phase. In vivo, formulations containing MCT led to lower or similar concentrations of CBD in serum, lymph and MLNs, but with reduced variability. MCT improves the emulsification and micellar solubilization of CBD, but surfactants did not facilitate further the rate and extent of lipolysis. Even though addition of MCT reduces the variability, the in vivo performance for the extent of both lymphatic transport and systemic bioavailability remains superior with a pure natural oil vehicle.
- Open Access
Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
Male hypogonadism is often treated by testosterone (T) replacement therapy such as oral administration of the ester prodrug, testosterone undecanoate (TU). However, the systemic exposure to T following oral TU is very low due to esterase-mediated metabolism, particularly in the small intestine. The aim of this work was to examine the esterase-inhibitory effect of natural fruit extract of strawberry (STW) on the intestinal degradation of TU as a potential approach to increasing the oral bioavailability of T. Herein, the hydrolysis of TU was assessed in fasted state simulated intestinal fluid with added esterase activity (FaSSIF/ES) and Caco-2 cell homogenates in the presence of STW extract. It is noteworthy that STW substantially inhibited the degradation of TU in FaSSIF/ES and Caco-2 cell homogenates at concentrations that could be achieved following oral consumption of less than one serving of STW fruit. This can significantly increase the fraction of unhydrolyzed TU in the intestinal lumen as well as in enterocytes. In addition, it was demonstrated that TU has high intestinal lymphatic transport potential as the association of TU with plasma-derived human chylomicrons was in the range of 84%. Therefore, oral co-administration of TU with STW could potentially increase the intestinal stability of TU and consequently the contribution of lymphatically delivered TU to the systemic exposure of T in vivo.
Open AccessStrawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
Male hypogonadism is often treated by testosterone (T) replacement therapy such as oral administration of the ester prodrug, testosterone undecanoate (TU). However, the systemic exposure to T following oral TU is very low due to esterase-mediated metabolism, particularly in the small intestine. The aim of this work was to examine the esterase-inhibitory effect of natural fruit extract of strawberry (STW) on the intestinal degradation of TU as a potential approach to increasing the oral bioavailability of T. Herein, the hydrolysis of TU was assessed in fasted state simulated intestinal fluid with added esterase activity (FaSSIF/ES) and Caco-2 cell homogenates in the presence of STW extract. It is noteworthy that STW substantially inhibited the degradation of TU in FaSSIF/ES and Caco-2 cell homogenates at concentrations that could be achieved following oral consumption of less than one serving of STW fruit. This can significantly increase the fraction of unhydrolyzed TU in the intestinal lumen as well as in enterocytes. In addition, it was demonstrated that TU has high intestinal lymphatic transport potential as the association of TU with plasma-derived human chylomicrons was in the range of 84%. Therefore, oral co-administration of TU with STW could potentially increase the intestinal stability of TU and consequently the contribution of lymphatically delivered TU to the systemic exposure of T in vivo.
- 1 January 2021
- Published by Elsevier in Journal of Controlled Release
- Vol. 329, 1077-1089
Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach
- 1 January 2021
- Published by Elsevier in Journal of Controlled Release
- Vol. 329, 1077-1089
Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach
- Open Access
- 18 October 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (20) , 7283
Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate
The bioavailability of orally administered drugs could be impacted by intestinal and hepatic first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of TU in microsomal mixtures was 28.31 ± 3.51 min. By applying the “well-stirred” model, the fraction of TU that could escape hepatic first-pass metabolism (FH) was predicted as 0.915 ± 0.009. The incubation of TU in Caco-2 cell homogenate yielded t1/2 inv of 109.28 ± 21.42 min, which was applied in a “Q gut” model to estimate the fraction of TU that would escape intestinal first-pass metabolism (FG) as 0.114 ± 0.02. Accordingly, only 11% of the absorbed fraction of TU could escape intestinal metabolism, while 91% can pass through hepatic metabolism. Hence, compared to the liver, the intestinal wall is the main site where TU is significantly metabolised during first-pass effect.
- 18 October 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (20) , 7283
Open AccessPredicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate
The bioavailability of orally administered drugs could be impacted by intestinal and hepatic first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of TU in microsomal mixtures was 28.31 ± 3.51 min. By applying the “well-stirred” model, the fraction of TU that could escape hepatic first-pass metabolism (FH) was predicted as 0.915 ± 0.009. The incubation of TU in Caco-2 cell homogenate yielded t1/2 inv of 109.28 ± 21.42 min, which was applied in a “Q gut” model to estimate the fraction of TU that would escape intestinal first-pass metabolism (FG) as 0.114 ± 0.02. Accordingly, only 11% of the absorbed fraction of TU could escape intestinal metabolism, while 91% can pass through hepatic metabolism. Hence, compared to the liver, the intestinal wall is the main site where TU is significantly metabolised during first-pass effect.